Copyright
©The Author(s) 2022.
World J Gastrointest Oncol. Apr 15, 2022; 14(4): 920-934
Published online Apr 15, 2022. doi: 10.4251/wjgo.v14.i4.920
Published online Apr 15, 2022. doi: 10.4251/wjgo.v14.i4.920
No. | Age (yr) | Sex | ECOG PS | Primary tumor | Site of metastases | Liver metastases | RAS and BRAF mutation | Lines of treatment | Prior 5-Fu | Prior platinum | Prior irinotecan | Prior bevacizumab | Prior cetuximab | Prior regorafenib | Prior PD-1 |
1 | 56 | Female | 1 | Sigmoid colon | Abdominal metastases | No | Wild-type | 3 | Yes | Yes | Yes | Yes | Yes | No | No |
2 | 62 | Female | 3 | Ascending colon | Multiple metastases | Yes | Not tested | 4 | Yes | Yes | Yes | Yes | No | Yes | No |
3 | 51 | Female | 0 | Rectum | Multiple metastases | Yes | Not tested | 3 | Yes | Yes | Yes | Yes | No | No | No |
4 | 52 | Female | 1 | Sigmoid colon | Multiple metastases | No | KRAS mutation | 3 | Yes | Yes | Yes | Yes | No | No | No |
5 | 66 | Female | 1 | Ascending colon | Multiple metastases | Yes | Not tested | 4 | Yes | Yes | Yes | Yes | No | Yes | No |
6 | 57 | Female | 2 | Sigmoid colon | Multiple metastases | No | Wild-type | 3 | Yes | Yes | Yes | Yes | Yes | No | No |
7 | 48 | Female | 3 | Liver curvature of the transverse colon | Multiple metastases | Yes | Not tested | 3 | Yes | Yes | Yes | Yes | No | No | No |
8 | 61 | Female | 2 | Rectum | Pelvic metastases | No | KRAS mutation | 3 | Yes | Yes | Yes | Yes | No | No | No |
9 | 65 | Female | 1 | Rectum | Ovary metastases | No | Wild-type | 4 | Yes | Yes | Yes | Yes | Yes | Yes | No |
10 | 65 | Female | 0 | Ascending colon | Lung metastases | No | Not tested | 3 | Yes | Yes | Yes | Yes | No | No | No |
11 | 56 | Female | 2 | Left half of the colon | Ovary metastases | No | Wild-type | 3 | Yes | Yes | Yes | Yes | Yes | No | No |
12 | 27 | Male | 0 | Sigmoid colon | Pelvic metastases | No | Wild-type | 4 | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
13 | 58 | Male | 1 | Sigmoid colon | Liver metastases | Yes | Not tested | 3 | Yes | Yes | Yes | Yes | No | No | No |
14 | 70 | Female | 1 | Rectum | Lung metastases | No | Not tested | 4 | Yes | Yes | Yes | Yes | No | No | No |
15 | 54 | Male | 1 | Ascending colon | Multiple metastases | Yes | KRAS mutation | 3 | Yes | Yes | Yes | Yes | No | No | No |
16 | 55 | Male | 1 | Rectum | Multiple metastases | Yes | NRAS mutation | 4 | Yes | Yes | Yes | Yes | No | Yes | No |
17 | 48 | Female | 0 | Rectum | Multiple metastases | Yes | Wild-type | 3 | Yes | Yes | Yes | Yes | Yes | No | No |
18 | 55 | Male | 1 | Rectum | Multiple metastases | Yes | Wild-type | 3 | Yes | Yes | Yes | Yes | Yes | No | No |
19 | 64 | Male | 2 | Rectum | Multiple metastases | Yes | KRAS mutation | 3 | Yes | Yes | Yes | Yes | No | No | No |
20 | 58 | Female | 0 | Ascending colon | Multiple metastases | Yes | Wild-type | 3 | Yes | Yes | Yes | Yes | Yes | No | No |
21 | 44 | Female | 2 | Sigmoid colon | Multiple metastases | Yes | Wild-type | 3 | Yes | Yes | Yes | Yes | Yes | No | No |
22 | 51 | Male | 1 | Rectum | Multiple metastases | Yes | Not tested | 4 | Yes | Yes | Yes | Yes | No | Yes | No |
23 | 56 | Male | 1 | Rectum | Lung metastases | No | Not tested | 4 | Yes | Yes | Yes | Yes | No | No | No |
24 | 61 | Male | 2 | Rectum | Multiple metastases | Yes | Not tested | 4 | Yes | Yes | Yes | Yes | No | No | No |
25 | 73 | Male | 0 | Rectum | Multiple metastases | Yes (radiofrequency) | Wild-type | 3 | Yes | Yes | Yes | Yes | Yes | No | No |
26 | 61 | Male | 1 | Rectum | Multiple metastases | Yes | Wild-type | 4 | Yes | Yes | Yes | Yes | Yes | Yes | No |
27 | 58 | Male | 2 | Sigmoid colon | Multiple metastases | No | KRAS mutation | 3 | Yes | Yes | Yes | Yes | No | No | No |
28 | 57 | Female | 1 | Sigmoid colon | Liver metastases | Yes (hepatectomy) | KRAS mutation | 3 | Yes | Yes | Yes | Yes | No | No | No |
29 | 67 | Male | 2 | Rectum | Liver metastases | Yes | Not tested | 3 | Yes | Yes | Yes | Yes | No | No | No |
30 | 61 | Male | 1 | Sigmoid colon | Peritoneal metastasis | No | Wide-type | 3 | Yes | Yes | Yes | Yes | Yes | No | No |
No. | Initial dose of regorafenib (mg) | Dose adjustment (mg) | PD-1 inhibitor used in combination | Number of treatment cycles | Best response | PFS (mo) | OS (mo) |
1 | 120 | Camrelizumab | 16 | SD | 11.2 | 12.0 | |
2 | 80 | Tislelizumab | 7 | SD | 5.0 | 7.0 | |
3 | 160 | 160→80 | Nivolumab | 4 | PD | 3.4 | Not reached |
4 | 80 | Camrelizumab | 4 | PD | 3.4 | 4.0 | |
5 | 80 | Tislelizumab | 3 | SD | 2.0 | 5.0 | |
6 | 80 | Toripalimab | 5 | SD | 3.5 | Not reached | |
7 | 80 | Tislelizumab | 7 | SD | 5.0 | 9.0 | |
8 | 80 | Pembrolizumab | 5 | PD | 3.5 | Not reached | |
9 | 120 | Sintilimab | 4 | SD | 2.8 | Not reached | |
10 | 160 | 160→80 | Toripalimab | 8 | SD | 5.6 | Not reached |
11 | 80 | Tislelizumab | 2 | SD | 1.4 | Not reached | |
12 | 160 | Toripalimab | 4 | SD | 2.8 | Not reached | |
13 | 120 | Nivolumab | 6 | SD | 4.2 | Not reached | |
14 | 80 | Toripalimab | 5 | SD | 3.5 | Not reached | |
15 | 120 | Sintilimab | 6 | SD | 3.5 | Not reached | |
16 | 80 | Nivolumab | 15 | SD | 10.5 | Not reached | |
17 | 160 | 160→80 | Sintilimab | 4 | PD | 2.8 | Not reached |
18 | 80 | Camrelizumab | 5 | PD | 3.5 | Not reached | |
19 | 80 | Toripalimab | 2 | SD | 1.4 | Not reached | |
20 | 120 | Camrelizumab | 4 | PD | 3.4 | 7.0 | |
21 | 80 | Toripalimab | 2 | PD | 1.4 | Not reached | |
22 | 120 | Camrelizumab | 1 | SD | 0.7 | 12.0 | |
23 | 80 | Sintilimab | 2 | PD | 1.4 | 10.0 | |
24 | 80 | Toripalimab | 9 | SD | 6.3 | 11.0 | |
25 | 120 | 120→80 | Sintilimab | 2 | PD | 1.4 | Not reached |
26 | 80 | Sintilimab | 3 | SD | 2.1 | 10.0 | |
27 | 80 | Toripalimab | 6 | SD | 4.2 | Not reached | |
28 | 120 | Sintilimab | 2 | PD | 1.4 | Not reached | |
29 | 80 | Sintilimab | 1 | PD | 0.7 | not reached | |
30 | 80 | Sintilimab | 2 | PD | 1.4 | Not reached |
Adverse event | Number of patients (n = 30), n (%) | ||
Any grade | Grade 1-2 | Grade 3 | |
Any event | 17 (56.7) | 13 (43.3) | 4 (13.3) |
Hand-foot syndrome | 10 (33.3) | 8 (26.7) | 2 (6.7) |
Hypertension | 7 (23.3) | 7 (23.3) | 0 |
Malaise | 6 (20.0) | 6 (20.0) | 0 |
Gastrointestinal reaction | 5 (16.7) | 5 (16.7) | 0 |
Transaminase elevation | 4 (13.3) | 3 (10.0) | 1 (3.3) |
Diarrhea | 3 (10.0) | 3 (10.0) | 0 |
Abnormal capillary proliferation | 2 (6.7) | 1 (3.3) | 1 (3.3) |
Hypothyroidism | 2 (6.7) | 2 (6.7) | 0 |
Proteinuria | 2 (6.7) | 2 (6.7) | 0 |
Rash | 2 (6.7) | 2 (6.7) | 0 |
Thrombocytopenia | 2 (6.7) | 2 (6.7) | 0 |
Anemia | 1 (3.3) | 1 (3.3) | 0 |
Myocardial enzyme elevation | 1 (3.3) | 1 (3.3) | 0 |
Oral mucositis | 1 (3.3) | 1 (3.3) | 0 |
Leukopenia/neutropenia | 0 | 0 | 0 |
- Citation: Xu YJ, Zhang P, Hu JL, Liang H, Zhu YY, Cui Y, Niu P, Xu M, Liu MY. Regorafenib combined with programmed cell death-1 inhibitor against refractory colorectal cancer and the platelet-to-lymphocyte ratio’s prediction on effectiveness. World J Gastrointest Oncol 2022; 14(4): 920-934
- URL: https://www.wjgnet.com/1948-5204/full/v14/i4/920.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v14.i4.920